MGNX MACROGENICS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1125345 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.8%
TTM net income YoY32.1%
TTM EPS YoY33.9%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-70.2%
Net margin-45.4%
FCF margin-36.4%
EBITDA margin-66.4%
Returns
ROE-111.8%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets92.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage-4.52x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.67M | $32.83M | $20.77M | $41.23M | $53.00M | $6.87M | $13.19M | $19.35M |
| Cost of revenue | — | — | — | $0 | $0 | $0 | $0 | $233,000 |
| Gross profit | — | — | — | $41.23M | $53.00M | $6.87M | $13.19M | $19.12M |
| R&D expense | $30.61M | $38.78M | $34.97M | $33.97M | $32.71M | $40.79M | $39.70M | $38.89M |
| SG&A expense | $8.36M | $7.90M | $9.71M | $9.23M | $9.90M | $9.30M | $10.72M | $27.81M |
| Operating income | -$20.30M | -$13.85M | -$33.44M | -$12.10M | $10.39M | -$43.22M | -$42.62M | -$52.84M |
| Interest expense | $4.08M | $4.40M | $4.89M | $4.27M | $3.34M | $802,000 | $91,000 | -$24,000 |
| Pretax income | -$21.48M | -$69.64M | — | -$14.93M | $8.57M | -$42.61M | — | -$14.48M |
| Income tax | $0 | $0 | — | -$777,000 | $0 | $105,000 | — | $944,000 |
| Net income | -$20.08M | $19.52M | -$36.77M | -$14.15M | $16.82M | -$36.25M | -$41.04M | -$15.42M |
| EBITDA | -$20.10M | -$13.14M | -$31.75M | -$10.39M | $12.18M | -$41.32M | -$40.85M | -$50.78M |
| EPS (basic) | -0.32 | 0.31 | -0.58 | — | 0.27 | -0.57 | -0.65 | — |
| EPS (diluted) | -0.32 | 0.31 | -0.58 | — | 0.27 | -0.57 | -0.65 | — |
| Weighted avg. shares (diluted) | 63.74M | 63.59M | 63.45M | — | 63.28M | 63.14M | 62.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $49.03M | $113.91M | $66.52M | $57.22M | $80.13M | $130.69M | $145.57M | $182.84M |
| Receivables | $435,000 | $24.60M | $10.43M | $427,000 | $69.23M | $12.53M | $10.54M | $4.31M |
| Inventory | — | — | $9.50M | $7.91M | $8.75M | $9.28M | $9.43M | $0 |
| Current assets | $295.08M | $321.69M | $182.52M | $219.94M | $232.09M | $204.94M | $182.09M | $217.49M |
| PP&E, net | $2.23M | $2.39M | $11.49M | $2.10M | $13.97M | $15.36M | $16.88M | $18.10M |
| Total assets | $318.69M | $345.41M | $217.87M | $256.85M | $270.76M | $245.42M | $224.56M | $261.65M |
| Current liabilities | $107.23M | $108.81M | $95.94M | $43.12M | $44.47M | $39.00M | $55.44M | $55.53M |
| Total liabilities | $293.53M | $302.54M | $196.68M | $201.25M | $203.76M | $198.80M | $145.45M | $145.60M |
| Shareholders' equity | $25.15M | $42.87M | $21.20M | $55.59M | $67.00M | $46.62M | $79.12M | $116.06M |
| Shares outstanding | 63.88M | 63.65M | 63.56M | 63.32M | 63.26M | 63.21M | 63.09M | 62.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.33M | -$40.75M | -$35.81M | $43.02M | -$30.19M | -$46.98M | -$46.89M | -$38.41M |
| Capital expenditure | $72,000 | $806,000 | $344,000 | $244,000 | $426,000 | $715,000 | $529,000 | $620,000 |
| Free cash flow | -$6.40M | -$41.55M | -$36.16M | $42.78M | -$30.61M | -$47.70M | -$47.42M | -$39.03M |
| Investing cash flow | -$59.14M | $27.96M | $45.32M | -$65.99M | -$20.37M | -$37.64M | $9.90M | $41.47M |
| Financing cash flow | $590,000 | $60.17M | -$207,000 | $57,000 | $0 | $69.74M | -$282,000 | $155,000 |
| Depreciation & amortization | $199,000 | $708,000 | $1.69M | $1.71M | $1.79M | $1.91M | $1.77M | $2.05M |
| Stock-based compensation | $2.06M | $1.97M | $2.65M | $2.66M | $3.55M | $3.69M | $4.39M | $11.27M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.